Loading clinical trials...
Loading clinical trials...
Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fa...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Henan Cancer Hospital
Collaborators
NCT07471841 · IDH1 Mutation, Relapsed / Refractory AML
NCT06352242 · Diffuse Large B Cell Lymphoma
NCT07072247 · Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
NCT07082868 · Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, and more
NCT06257056 · Treatment-Refractory Schizophrenia
Henan Cancer Hospital
Zhengzhou, Henan
Henan Cancer Hospital
Zhengzhou, Henan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions